Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
Jordi Remón, Benjamin Besse, Santiago Ponce Aix, Ana Callejo, K. Al-Rabi, Reyes Bernabé, L. Greillier, Margarita Majem, Noemı́ Reguart, I. Monnet, S. Cousin, Pilar Garrido, G. Robinet, Rosario García Campelo, A. Madroszyk, Julien Mazières, H. Curcio, Bartosz Wasąg, Y. Pretzenbacher, B. Fournier, Anne‐Marie C. Dingemans, Rafał Dziadziuszko
Topics & Concepts
MedicineOsimertinibT790Mnon-small cell lung cancer (NSCLC)Lung cancerOncologyInternal medicineRandomized controlled trialClinical trialAdenocarcinomaCancerEpidermal growth factor receptorErlotinibA549 cellROS1Lung Cancer Treatments and MutationsLung Cancer Research StudiesFibroblast Growth Factor Research